Gerd Maass

HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.

Petra Heinmöller, Kurt Beyser, C. Schmidtgen et al. · PubMed · 2003 · 184 citations

Cancer vaccines: the interleukin 2 dosage effect.

Wolfgang Schmidt, Tamás Schweighoffer, E Herbst et al. · Proceedings of the National Academy of Sciences · 1995 · 127 citations · Full text

Immunology, Immunologic Mechanism, Protection Efficiency +17

Infectious foot-and-mouth disease virus derived from a cloned full-length cDNA

Andree Zibert, Gerd Maass, Klaus Strebel et al. · Journal of Virology · 1990 · 103 citations · Full text

Viral Replication, Full-length Cdna, Foot-and-mouth Disease Virus +13

Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination.

Gerd Maass, Wolfgang Schmidt, M Berger et al. · Proceedings of the National Academy of Sciences · 1995 · 95 citations · Full text

Immunology, Immunologic Mechanism, Immunotherapy +17

Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.

Kurt Zatloukal, Achim Schneeberger, M Berger et al. · The Journal of Immunology · 1995 · 88 citations

Immunology, Immunoediting, Il-2 Gene Construct +18